HR0123LRB103 31336 LAW 58770 r

1
HOUSE RESOLUTION

 
2    WHEREAS, The members of the Illinois House of
3Representatives wish to congratulate CSL Behring on the
4occasion of operating its manufacturing facility in the
5Kankakee region for 70 successful years; and
 
6    WHEREAS, CSL Behring's parent company, CSL, is a leading
7global biotechnology company with a dynamic portfolio of
8medicines that provide lifesaving products to patients in more
9than 100 countries; and
 
10    WHEREAS, CSL Plasma, a CSL company, operates one of the
11world's largest and most sophisticated plasma collection
12networks throughout the United States; in Illinois, it
13operates 15 centers that collect plasma used for the sole
14purpose of manufacturing plasma-derived therapies; and
 
15    WHEREAS, CSL is opening its newest plasma collection
16center on the south campus of its Kankakee manufacturing site,
17thereby continuing to build on its presence in the Kankakee
18region; and
 
19    WHEREAS, CSL, a global biotech leader that discovers,
20develops, and delivers innovative therapies so patients can
21live their lives to the fullest, has recently launched

 

 

HR0123- 2 -LRB103 31336 LAW 58770 r

1HEMGENIX®, the first and only gene therapy treatment to treat
2severe Hemophilia B; therefore, be it
 
3    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
4HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
5we congratulate CSL Behring for its 70 years in the Kankakee
6region and throughout the State of Illinois, addressing unmet
7medical needs and helping patients around the world live full
8lives; and be it further
 
9    RESOLVED, That a suitable copy of this resolution be
10presented to CSL Behring as an expression of our esteem and
11respect.